Chao Song

Chao Song


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
QSQianlin Song
Qianlin Song
WLWenbiao Liao
Wenbiao Liao
XCXin Chen
Xin Chen
ZHZiqi He
Ziqi He
DLDe Li
De Li
SYSixing Yang
Sixing Yang
Renal tubular epithelial cell damage is the basis for the formation of kidney stones. Oxalate can induce human proximal tubular (HK‐2) cells to undergo autophagy and ferroptosis. The present study was aimed at investigating whether the ferroptosis of HK‐2 cells induced by oxalate is caused by the excessive activation of autophagy. We treated HK‐2 cells with 2 mmol/L of oxalate to establish a kidney stone model. First, we tested the degree of oxidative damage and the level of autophagy and ferroptosis in the control group and the oxalate intervention group. We then knocked down and overexpressed the BECN1 gene and knocked down the NCOA4 gene in HK‐2 cells, followed by redetection of the above indicators. We confirmed that oxalate could induce autophagy and ferroptosis in HK‐2 cells. Moreover, after oxalate treatment, overexpression of the BENC1 gene increased cell oxidative damage and ferroptosis. In addition, knockdown of NCOA4 reversed the effect of oxalate‐induced ferroptosis in HK‐2 cells. Our results show that the effects of oxalate on the ferroptosis of HK‐2 cells are caused by the activation of autophagy, and knockdown of the NCOA4 could ameliorate this effect.

2 January 2024 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
JLJunwei Liu
Junwei Liu
YGYue Gao
Yue Gao
CSChao Song
Chao Song
WLWenbiao Liao
Wenbiao Liao
LMLingchao Meng
Lingchao Meng
YXYunhe Xiong
Yunhe Xiong
Bladder cancer is one of the most common malignant tumours of the urogenital system, with high morbidity and mortality. In most cases, surgery is considered the first choice of treatment, followed by adjuvant chemotherapy. However, the 5‐year recurrence rate is still as high as 65% in patients with non‐invasive or in situ tumours and up to 73% in patients with slightly more advanced disease at initial diagnosis. Various treatment methods for bladder cancer have been developed, and hundreds of new immunotherapies are being tested. To date, only a small percentage of people have had success with new treatments, though studies have suggested that the combination of immunotherapy with other therapies improves treatment efficiency and positive outcomes for individuals, with great hopes for the future. In this article, we summarize the origins, therapeutic mechanisms and current status of research on immunotherapeutic agents for bladder cancer.

25 February 2022 in Surgical Endoscopy
Verified
Journal Article
Open access
PDF file
PSParesh C. Shah
Paresh C. Shah
AGAlexander de Groot
Alexander de Groot
RCRobert Cerfolio
Robert Cerfolio
WHWilliam C. Huang
William C. Huang
KHKathy Huang
Kathy Huang
DODaniel Oh
Daniel Oh